H
Harald Stephan
Researcher at University of Duisburg-Essen
Publications - 18
Citations - 708
Harald Stephan is an academic researcher from University of Duisburg-Essen. The author has contributed to research in topics: Retinoblastoma & Neuroblastoma. The author has an hindex of 12, co-authored 18 publications receiving 581 citations. Previous affiliations of Harald Stephan include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Mutational dynamics between primary and relapse neuroblastomas
Alexander Schramm,Johannes Köster,Johannes Köster,Yassen Assenov,Kristina Althoff,Martin Peifer,E Mahlow,Andrea Odersky,Daniela Beisser,Corinna Ernst,Anton G. Henssen,Anton G. Henssen,Anton G. Henssen,Harald Stephan,Christopher Schröder,Lukas C. Heukamp,Anne Engesser,Yvonne Kahlert,Jessica Theissen,Barbara Hero,Frederik Roels,Janine Altmüller,Peter Nürnberg,Kathy Astrahantseff,Christian Gloeckner,Katleen De Preter,Christoph Plass,Sangkyun Lee,Holger N. Lode,Kai Oliver Henrich,Moritz Gartlgruber,Frank Speleman,Peter Schmezer,Frank Westermann,Sven Rahmann,Sven Rahmann,Matthias Fischer,Angelika Eggert,Angelika Eggert,Johannes H. Schulte,Johannes H. Schulte,Johannes H. Schulte +41 more
TL;DR: The mutational burden significantly increased in relapsing tumors, accompanied by altered mutational signatures and reduced subclonal heterogeneity and global allele frequencies at relapse indicated clonal mutation selection during disease progression.
Journal ArticleDOI
Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma
Corinna Grasemann,Sandrine Gratias,Harald Stephan,Andreas Schüler,Alexander Schramm,Ludger Klein-Hitpass,Harald Rieder,Stephanie Schneider,Ferdinand Kappes,Angelika Eggert,Dietmar R. Lohmann +10 more
TL;DR: The results suggest that DEK and E2F3 are potential targets of 6p gains in retinoblastoma, and expression levels of these and some other genes in 6p22 correspond to DNA gains.
Journal ArticleDOI
Genomic gains on chromosome 1q in retinoblastoma: consequences on gene expression and association with clinical manifestation.
Sandrine Gratias,Andreas Schüler,Ludger Klein Hitpass,Harald Stephan,Harald Rieder,Harald Rieder,Stephanie Schneider,Bernhard Horsthemke,Dietmar R. Lohmann +8 more
TL;DR: The clinical manifestation of tumors with and without gains was similar with regard to many aspects, including size, necrosis and calcification, but the distribution of age at diagnosis was remarkably distinct, with earlier diagnosis in tumors without gains suggesting that these tumors either are initiated earlier or grow faster than tumors with gains.
Journal ArticleDOI
MiR-34a deficiency accelerates medulloblastoma formation in vivo.
Theresa Thor,Theresa Thor,A Künkele,Kristian W. Pajtler,Annika K. Wefers,Harald Stephan,Pieter Mestdagh,Lukas C. Heukamp,Wolfgang Hartmann,Jo Vandesompele,Natalie Sadowski,Lore Becker,Lillian Garrett,Sabine M. Hölter,Marion Horsch,Julia Calzada-Wack,Tanja Klein-Rodewald,Ildiko Racz,Andreas Zimmer,Johannes Beckers,Frauke Neff,Thomas Klopstock,Pasqualino De Antonellis,Massimo Zollo,Wolfgang Wurst,Helmut Fuchs,Valerie Gailus-Durner,Ulrich Schüller,Martin Hrabě de Angelis,Angelika Eggert,Alexander Schramm,Johannes H. Schulte +31 more
TL;DR: It is demonstrated that miR‐34a is dispensable for normal development, but that its loss accelerates medulloblastomagenesis and strategies aiming to re‐express miR-34a in tumors could, therefore, represent an efficient therapeutic option.
Journal ArticleDOI
Photodynamic therapy in retinoblastoma: effects of verteporfin on retinoblastoma cell lines.
TL;DR: In this paper, the effects of photochemotherapy using second-generation photochemotherapeutics as a prerequisite to develop a promising therapeutic alternative for the malignant childhood tumor retinoblastoma (RB) were evaluated.